Stockreport

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]

Inhibrx, Inc.  (INBX) 
PDF INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is [Read more]